CU20200106A7 - Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias - Google Patents

Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias

Info

Publication number
CU20200106A7
CU20200106A7 CU2020000106A CU20200106A CU20200106A7 CU 20200106 A7 CU20200106 A7 CU 20200106A7 CU 2020000106 A CU2020000106 A CU 2020000106A CU 20200106 A CU20200106 A CU 20200106A CU 20200106 A7 CU20200106 A7 CU 20200106A7
Authority
CU
Cuba
Prior art keywords
methods
compositions
thalasemias
hemoglobinopathies
treatment
Prior art date
Application number
CU2020000106A
Other languages
English (en)
Inventor
Russell Matthew
Afeyan Raffi
Carroll Sean
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CU20200106A7 publication Critical patent/CU20200106A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0606—Arginine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0612—Carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/062—Glutamine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0624—Histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/063—Lysine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0642—Serine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente divulgación proporciona composiciones y métodos para mejorar la disfunción de eritrocitos o tratar una hemoglobinopatía o una talasemia (por ejemplo, anemia de células falciformas o beta-talasemia).</p>
CU2020000106A 2018-06-20 2019-06-16 Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias CU20200106A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687721P 2018-06-20 2018-06-20
US201962804879P 2019-02-13 2019-02-13
PCT/US2019/037925 WO2019246214A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the treatment of hemoglobinopathies and thalassemias

Publications (1)

Publication Number Publication Date
CU20200106A7 true CU20200106A7 (es) 2021-08-06

Family

ID=67482969

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000106A CU20200106A7 (es) 2018-06-20 2019-06-16 Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias

Country Status (20)

Country Link
US (2) US11058654B2 (es)
EP (1) EP3809881A1 (es)
JP (1) JP2021528414A (es)
KR (1) KR20210022054A (es)
CN (1) CN112654263A (es)
AU (1) AU2019290620A1 (es)
BR (1) BR112020026110A2 (es)
CA (1) CA3104279A1 (es)
CL (1) CL2020003276A1 (es)
CU (1) CU20200106A7 (es)
EA (1) EA202190073A1 (es)
EC (1) ECSP20081995A (es)
IL (1) IL279467A (es)
JO (1) JOP20200325A1 (es)
MX (1) MX2020013833A (es)
PE (1) PE20210371A1 (es)
PH (1) PH12020552212A1 (es)
SG (1) SG11202012714QA (es)
TW (1) TW202015667A (es)
WO (1) WO2019246214A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
JP2021529735A (ja) 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． アミノ酸組成物の製造方法
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US20230000808A1 (en) * 2019-12-06 2023-01-05 Axcella Health Inc. Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias
CN112336710A (zh) * 2020-12-27 2021-02-09 西北农林科技大学 谷氨酰胺在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用
WO2023009444A1 (en) 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5693671A (en) 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
CA2439293A1 (en) * 2001-03-05 2002-09-12 Stephen P. Ernest Enteral formulation
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
WO2004073623A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
JP2005272410A (ja) * 2004-03-26 2005-10-06 Ajinomoto Co Inc 抗動脈硬化用及び／又は血液レオロジー改善用経口アミノ酸組成物
WO2006002096A2 (en) 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Low doses of l-citrulline for treating diseases
CA2587647C (en) 2004-12-01 2017-03-28 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20120316121A1 (en) 2005-07-28 2012-12-13 Allen Ann De Wees Materials and Methods for Modulating Arginine Metabolism
JP5316918B2 (ja) * 2006-04-24 2013-10-16 味の素株式会社 透析患者用輸液剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CA2668184A1 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
CN100518815C (zh) 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
WO2009149196A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc. Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US9089548B2 (en) 2011-11-15 2015-07-28 Tima Foundation Composition for protection against cell-damaging effects
RU2662917C2 (ru) 2011-12-19 2018-07-31 Иммаус Медикал, Инк. Способы и композиции для лечения дивертикулёза
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
RU2016110800A (ru) 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3626707A1 (en) 2014-01-13 2020-03-25 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
WO2015127163A1 (en) 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
WO2015165842A1 (en) * 2014-04-30 2015-11-05 F. Hoffmann-La Roche Ag Glyt1 inhibitors for use in the treatment of hematological disorders
US20170087180A1 (en) 2014-06-03 2017-03-30 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
US9822190B2 (en) 2015-01-29 2017-11-21 Shaker A. Mousa Compositions and method for anti-sickling of red blood cells in sickle cell disease
CN109562091A (zh) 2016-08-05 2019-04-02 费森尤斯卡比德国有限公司 用于保留、改善或恢复肾功能的谷氨酰胺
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AR111082A1 (es) 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
JP7370960B2 (ja) 2017-08-14 2023-10-30 アクセラ・ヘルス・インコーポレイテッド 神経細胞損傷の治療のためのアミノ酸組成物
JP2021529735A (ja) 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． アミノ酸組成物の製造方法
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
MX2020013731A (es) 2018-06-20 2021-02-26 Axcella Health Inc Composiciones para terapia y salud que contienen aminoacidos con sabor amargo.

Also Published As

Publication number Publication date
WO2019246214A8 (en) 2020-02-20
AU2019290620A1 (en) 2021-01-14
BR112020026110A2 (pt) 2021-03-16
CL2020003276A1 (es) 2021-07-09
US11058654B2 (en) 2021-07-13
MX2020013833A (es) 2021-03-25
IL279467A (en) 2021-01-31
US20210290574A1 (en) 2021-09-23
US20190388376A1 (en) 2019-12-26
EP3809881A1 (en) 2021-04-28
PE20210371A1 (es) 2021-02-26
ECSP20081995A (es) 2021-01-29
CA3104279A1 (en) 2019-12-26
CN112654263A (zh) 2021-04-13
JOP20200325A1 (ar) 2020-12-14
JP2021528414A (ja) 2021-10-21
PH12020552212A1 (en) 2021-08-16
TW202015667A (zh) 2020-05-01
SG11202012714QA (en) 2021-01-28
WO2019246214A1 (en) 2019-12-26
KR20210022054A (ko) 2021-03-02
EA202190073A1 (ru) 2021-04-12

Similar Documents

Publication Publication Date Title
CU20200106A7 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
ECSP21026021A (es) Moduladores de la expresión de pnpla3
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
EA201890641A3 (ru) Стимуляторы sgc
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
NI202000085A (es) Moduladores de la expresión de apol1
MX385269B (es) Compuesto de sulfonamida o sal del mismo.
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2021001246A1 (es) Moduladores de expresión irf5.
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
UY38472A (es) Moduladores de la expresión de foxp3
PE20200749A1 (es) Moduladores de la expresion de enac
AR117593A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
UA120068C2 (uk) Фунгіцидна композиція
CL2016002283A1 (es) Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición.
PY1659205A (es) Composiciones estables de inoculantes y métodos para producirlas
EA201992000A1 (ru) Улучшенные композиции и способы для бор-углеводных комплексов
AR117079A1 (es) Moduladores de la expresión de foxp3
EA202191657A1 (ru) Модуляторы экспрессии hsd17b13
AR108646A1 (es) Composiciones estables de inoculantes y métodos para producirlas
UA127733U (uk) Нанокомпозитний матеріал